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Syndrome and Nonsyndromic Enlargement of Vestibular
Aqueduct (DFNB4)
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Richard J. H. Smith
Although recessive mutations in the anion transporter gene SLC26A4 are known to be responsible for Pendred syndrome
(PS) and nonsyndromic hearing loss associated with enlarged vestibular aqueduct (EVA), also known as “DFNB4,” a large
percentage of patients with this phenotype lack mutations in the SLC26A4 coding region in one or both alleles. We have
identiﬁed and characterized a key transcriptional regulatory element in the SLC26A4 promoter that binds FOXI1, a
transcriptional activator of SLC26A4. In nine patients with PS or nonsyndromic EVA, a novel c.5103TrC mutation in
this regulatory element interferes with FOXI1 binding and completely abolishes FOXI1-mediated transcriptional acti-
vation. We have also identiﬁed six patients with mutations in FOXI1 that compromise its ability to activate SLC26A4
transcription. In one family, the EVA phenotype segregates in a double-heterozygous mode in the affected individual
who carries single mutations in both SLC26A4 and FOXI1. This ﬁnding is consistent with our observation that EVA occurs
in the Slc26a4+/5; Foxi1+/5 double-heterozygous mouse mutant. These results support a novel dosage-dependent model
for the molecular pathogenesis of PS and nonsyndromic EVA that involves SLC26A4 and its transcriptional regulatory
machinery.
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Pendred syndrome (PS [MIM 274600]) accounts for up
to 10% of hereditary hearing loss in humans, making it
the most common form of syndromic deafness.1 It is in-
herited in an autosomal recessive manner and has been
causally linked to mutations in the coding sequence of
SLC26A4 (MIM 605646; GenBank accession number
NC_000007.12).2,3 The disease phenotype is characterized
by sensorineural hearing loss; structural malformation of
the inner ear, such as enlargement of vestibular aqueduct
(EVA [MIM 603545]) with or without cochlear dysplasia;
and defects in iodide transport that can lead to goitrous
changes of the thyroid gland. Consistent with this phe-
notype, SLC26A4 mRNA and the encoded protein pendrin
are found in the inner ear and thyroid. In the inner ear,
pendrin is expressed in external sulcal cells and the en-
dolymphatic duct and sac—regions involved in endo-
lymph homeostasis4—and, in the thyroid, pendrin is ex-
pressed in the apical membrane of thyrocytes, where it
regulates iodide ﬂux into thyroid follicles.5,6 In addition
to PS, mutations in SLC26A4 also cause nonsyndromic
hearing loss with EVA in the absence of a thyroid phe-
notype (DFNB4 [MIM 600791]).7,8
Familial cases of both PS and nonsyndromic EVA sup-
port the recessive inheritance of this disease spectrum. In
previous reports,7,9,10 as well as in our current study (table
1), however, many patients segregate only one or no mu-
tations in the SLC26A4 coding region, suggesting that en-
vironmental or other genetic factors may contribute to
disease expression. The transcription-factor gene FOXI1
(MIM 601093) has been proposed as a candidate that may
contribute to the genetic cause of PS. Mice homozygous
for the targeted disruption of Foxi1 are deaf and have
EVA.11 Furthermore, there is complete absence of Slc26a4
(GenBank accession number NC_000078.4) expression in
the epithelial cells of endolymphatic duct and sac in
these mice, where normally both Foxi1 and Slc26a4 mes-
sages are present. These data suggest that Foxi1 (GenBank
accession number NP_076396.2) is an upstream regulator
of Slc26a4.12 In this study, we show that transcriptional
control of SLC26A4 expression involves a key cis-regula-
tory element in the SLC26A4 promoter and its associated
transcription factor FOXI1 (GenBank accession number
NP_036320.2), both of which play a role in the patho-
genesis of PS and nonsyndromic EVA.
Subjects and Methods
Subjects
Persons with EVA orMondini dysplasia were ascertained clinically
on the basis of the presence of hearing loss and ﬁndings of tem-
poral bone CT or magnetic resonance imaging. In addition to
these studies, their evaluation included a complete history and
physical examination. Thyroid defects were recorded but were
not used as classiﬁcation criteria. For their condition to be clas-
siﬁed as EVA, enlargement of the vestibular aqueduct had to be
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Table 1. Summary of SLC26A4 Mutation-
Screening Results in Patients with PS and
Nonsyndromic EVA
Families n
No. (%) of Families by No. of
SLC26A4 Mutations
Zero One Two
Multiplex 31 13 (42) 6 (19) 12 (39)
Simplex 398 284 (71) 69 (17) 45 (11)
Total 429 297 (69) 75 (17) 57 (13)
11.5 mm at a point midway between the endolymphatic sac and
the vestibule; to be classiﬁed as Mondini dysplasia, the cochlea
also had to be abnormal, with incomplete partition and a scala
communis. All procedures were approved by the institutional re-
view board at the University of Iowa, and informed consent was
obtained from all subjects.
Mutation Screening
Mutation screening was performed by denaturing high-perfor-
mance liquid chromatography and bidirectional sequencing on
DNA extracted from whole blood, as we have described else-
where.13,14 Mutation screening of SLC26A4 promoter and FOXI1
was completed in all patients with (1) one mutation in SLC26A4
or (2) nomutations in SLC26A4 but with either an affected sibling
or a classic PS phenotype (Mondini dysplasia with or without
goiter).
Luciferase Assay
FOXI1 was PCR ampliﬁed and cloned into the pcDNA3.1/zeo()
vector (Invitrogen). The 5-kb genomic region upstream of the
SLC26A4 start codon was ampliﬁed from control genomic DNA
by long-range PCR and was cloned into the luciferase reporter
vector pGL3.0 Basic (Promega). Mutant FOXI1 and SLC26A4 pro-
moter constructs were generated by site-directed mutagenesis, by
use of the QuikChange Site-DirectedMutagenesis Kit (Stratagene).
The SLC26A4 promoter-reporter assay was performed using the
Luciferase Assay System (Promega). In brief, COS-7 cells grown
in 6-well plates were transfected with 750 ng FOXI1 construct
and 250 ng luciferase reporter construct, with use of FUGENE 6
Transfection reagent (Roche). In place of FOXI1 constructs, 750
ng pcDNA3.1/zeo() empty vector was used in controls. Before
each luciferase assay, cell growth medium was carefully removed.
Cells were washed with PBS once, were mixed with 100 ml of 1#
lysis buffer, and were frozen at 20C for 20 min. Cells and all
lysates were scraped and transferred to microcentrifuge tubes,
were vortexed for 15 s, and were centrifuged at 12,000 g for 2
min at 4C. From each sample, 20 ml of the supernatant was
transferred to a 96-well plate for automatic luciferase activity
assay. Luciferase activities were determined as fold induction
compared with activities of corresponding control cells trans-
fected with 750 ng empty pcDNA3.1/zeo() vector and were nor-
malized to the total protein level measured by BicinchoninicAcid
Protein Assay Kit (Sigma). Experiments were performed in at least
triplicate.
Electrophoretic Mobility Shift Assay
FOXI1 protein was transcribed in vitro and was translated using
the TnT Quick Coupled Transcription/Translation System (Pro-
mega). As the DNA template, 1 mg pSP64 Poly(A) expression plas-
mid with the full FOXI1 coding sequence was used. Mobility shift
reactions were performed in 1# binding buffer (5 mM HEPES,
26% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithio-
threitol, 0.5 mM phenylmethylsulfonyl ﬂuoride, and 100 mM
KCl [pH 7.9]) supplemented with 1 ml poly d(I-C) in a 15-ml re-
action. Double-stranded oligonucleotide probes were 5′-end la-
beled with use of a32P-CTP and Klenow polymerase. Binding re-
actions contained 5#104 cpm of labeled probe, the indicated
amount of unlabeled competitor probe, and 3 ml protein lysate.
Binding reactions were incubated for 15min at room temperature
and were resolved using a nondenaturing 4% polyacrylamide gel.
Electrophoresis was performed at 4C at 200 V for 1.5 h, and the
gel was subjected to radioautography. Band intensity was quan-
tiﬁed using the AlphaEaseFC imaging system and software (Alpha
Innotech).
Histology
The morning that vaginal plugs were detected was designated
embryonic day 0.5 (E0.5). Tails from embryos were collected for
genotyping by use of PCR as described above. Embryos were ﬁxed
overnight in PBS with 4% paraformaldehyde at 4C. For histology,
embryos were dehydrated and embedded in parafﬁn wax, and 6-
mm sections were cut. Tissue sections were stained with hema-
toxylin and eosin for histological analysis. At least four mice of
each genotype were analyzed at E16.5.
Results
Identiﬁcation of an SLC26A4 Promoter Mutation Associated
with PS and Nonsyndromic EVA
We completed mutation screening of the SLC26A4 coding
region in 429 deaf probands given a diagnosis of EVAwith
or without cochlear dysplasia (table 1). In 31 multiplex
families with two or more affected siblings, only 12 (39%)
had sibships that segregated two disease-causing allele var-
iants of SLC26A4; in the remaining 398 simplex families,
the percentage was much lower (11%, or 45 families). In-
terestingly, one disease-causing mutation was identiﬁed
in 6 multiplex and 69 simplex families (17% of all fami-
lies). This ﬁnding suggested that additional genetic factors
are involved in PS and nonsyndromic EVA.
To study additional genetic causes of this disease, we
ﬁrst searched for mutations in the noncoding region of
SLC26A4 by screening its promoter. Three highly homol-
ogous regions in the 5-kb upstream sequence of SLC26A4
were found by comparing human and mouse genomes.
Mutation screening of these regions revealed a TrC single-
nucleotide change 103 bp upstream of the SLC26A4 trans-
lation start in nine families with PS or nonsyndromic EVA.
This c.103TrCmutation is within an evolutionarilycon-
served nucleotide among many mammalian species (ﬁg.
1A) and was not seen in 100 unrelated controls with nor-
mal hearing.
Functional Characterization of the Promoter Mutation
and the Embracing Regulatory Cis-Element
On the basis of comparison with the TRTTKRY FOXI1
consensus binding sequence ( ; ;Rp A/G Kp G/T Yp
)15,16 the c.103TrC promoter mutation lies withinC/T
Figure 1. FOXI1-binding afﬁnity to wild-type and mutant (c.103TrC) FBS1. A, Conservation of FBS1 and FBS2. FBS1 and FBS2 are
shown in bold, arrows indicate orientation, the c.103TrC mutation is indicated by the vertical arrow, and the oligonucleotide EMSA
probe is underlined. B, 32P-labeled double-stranded oligonucleotide probes containing FBS1 and FBS2 bind to FOXI1 protein as shift
bands. Protein binding to the mutant probe (lane 2) is signiﬁcantly weaker than that to the wild-type probe (lane 3). Protein binding
to the wild-type labeled probe was competed with either wild-type (lanes 4–7) or mutant (lanes 8–11) unlabeled competitor (10–100
molar fold excess). Mutant competitor competed signiﬁcantly less efﬁciently than wild-type competitor. C, Quantiﬁcation of EMSA
competition result: intensity of the top shift band of lanes 3–11 relative to the intensity of the top shift band without competition.
At 100# molar excess of competitor, the intensity of the top shift band drops to 0.12 fold for the wild-type competitor but to only
0.56 fold for the mutant competitor.
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Figure 2. Luciferase assay showing complete loss of FOXI1 tran-
scriptional activation in mutant and modiﬁed promoter-reporter
constructs. Top panel, Sequence of the FBS1-FBS2 promoter site
in various promoter-reporter constructs (from top to bottom): wild
type, c.103TrC mutant, FBS1 deletion, FBS1 inversion (Flip
FBS1), and FBS2 inversion (Flip FBS2). The 103C nucleotide is
marked with lowercase letters. Bottom panel, COS-7 cells were
transfected with 250 ng promoter-reporter construct and 750 ng
empty vector (white bars) or FOXI1 construct (gray bars). Reporter
activity is shown as “fold induction” compared with activity of
the wild-type promoter-reporter construct without exogenous ex-
pression of FOXI1. Results from three independent experiments are
shown (meanSD).
Table 2. List of Families with PS and






82230 Not noted E29Q/ G258E/
7980 Not noted / 161DelN/
8280 Not noted / G258R/
518350 Not noted / R267Q/
7390 Yes / R267Q/
81720 Yes / G335V/
NOTE.—All families have nonsyndromic EVA. p Wild-type
allele.
a predicted FOXI1-binding site highly conserved across
mammalian species, which we called “FBS1” (ﬁg. 1A). We
conﬁrmed binding of FOXI1 to FBS1 by electrophoresis
mobility shift assay (EMSA), which showed that the
c.103TrC mutation signiﬁcantly reduces FOXI1-bind-
ing afﬁnity (ﬁg. 1B).
To determine whether this promoter mutation directly
affects the transcription of SLC26A4, we used the lucif-
erase promoter-reporter expression assay. Five kilobases
of the upstream sequence of SLC26A4 were fused to the
luciferase reporter gene in the promoter-reporter con-
struct, which was transfected into COS-7 cells with FOXI1-
expressing constructs (see the “Subjects and Methods”
section). Compared with controls transfected with empty
vector, wild-type FOXI1 induced a sixfold increase in lu-
ciferase activity. However, when the c.103TrCmutation
was introduced into the SLC26A4 promoter-reporter con-
struct, FOXI1 transactivation of the luciferase reporter
was completely abolished (ﬁg. 2). The effect was identical
if FBS1 was deleted, implying that this binding site is a
major transcriptional regulatory element of SLC26A4 and
is required for FOXI1-induced transcriptional activation
of SLC26A4.
We identiﬁed a second FOXI1-binding site, called “FBS2,”
2 nt downstream of FBS1. FBS2 is also highly conserved
across species and is a perfect match to the TRTTKRY
consensus binding sequence, although in the reverse ori-
entation to FBS1 (ﬁg. 1A). Flipping either FBS1 or FBS2 in
the SLC26A4 promoter-reporter construct completely
abolishes any response to FOXI1 transcriptional activation
(ﬁg. 2), suggesting that the unique head-to-head orien-
tation of these tandem binding sites is necessary for FOXI1
to form a functional transcriptional-activation complex.
Identiﬁcation and Characterization of FOXI1 Mutations
We further asked whether mutations in FOXI1 contribute
to the PS-EVA disease spectrum. Mutation screening of
FOXI1 revealed ﬁve nonsynonymous variants of FOXI1 in
six patients (table 2). Three of these mutations—161DelN,
R267Q, and G335V—are conserved between human and
mouse, and the remaining two involve Gly258, changing
this small noncharged amino acid into either arginine or
glutamate, both of which are substantially more bulky
(ﬁg. 3). One mutation, 161DelN, is also unique, in that it
lies within the conserved forkhead DNA-binding domain.
None of the ﬁve mutations was seen in 250 unrelated
controls with normal hearing screened for FOXI1.
To study the possible effects of these FOXI1 mutations,
we ﬁrst completed immunoﬂuorescence assays of FOXI1
in mammalian cells transfected with mutant and wild-
type FOXI1 constructs and found that nuclear translo-
cation of the mutant protein was not altered (data not
shown). We then used the same promoter-reporter assay
system described in the promoter mutation study, to test
whether the FOXI1 mutations affect transcriptional acti-
vation. Compared with the sixfold induction of luciferase
expression by wild-type FOXI1, all ﬁve FOXI1 variants
showed signiﬁcantly decreased luciferase activation (ﬁg.
4). These results suggest that the variants in these patients
compromise FOXI1 transactivation ability of SLC26A4
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Figure 3. Conservation of human and mouse FOXI1 protein. The amino acid changes identiﬁed in patients with PS and nonsyndromic
EVA are underlined and marked by arrows. The conserved forkhead DNA-binding domain is shaded in gray.
expression and are causally related to disease in these
patients.
Double-Heterozygosity Model of Nonsyndromic EVA
In one family (82210) with hearing loss and nonsyn-
dromic EVA, the disease phenotype segregates in a dou-
ble-heterozygous mode, with the mother carrying the
SLC26A4 E29Q mutation, the father carrying the FOXI1
G258E mutation, the affected child carrying both muta-
tions, and the unaffected child carrying the SLC26A4
E29Q mutation only. Allele segregation in this family also
supports double heterozygosity, in that both siblings in-
herited the same two SLC26A4 alleles from their parents,
indicating that the difference in the phenotypes between
those two siblings is caused by mutations at another locus
(ﬁg. 5).
We crossed Slc26a4/ and Foxi1/ mice to determine
whether this animal model supports double heterozy-
gosity. Both Slc26a4/ and Foxi1/ mutants develop
EVA, whereas their heterozygous counterparts are phe-
notypically indistinguishable from wild-type controls.
In the Slc26a4/; Foxi1/ double-heterozygous mutant,
however, temporal bone development is abnormal, and
EVA is also observed (ﬁg. 6).
Discussion
Our work shows that the transcriptional machinery that
controls SLC26A4 expression is involved in the PS-EVA
disease spectrum. This ﬁnding is consistent with reports
by several investigators noting that many patients with a
PS-EVA phenotype lack mutations in either one or both
alleles of SLC26A4.7,9,10 Our database of 429 deaf probands
given clinical diagnoses of PS or nonsyndromic EVA rep-
resents the largest study to date to conﬁrm this observa-
tion (table 1). In only 39% of multiplex families and 11%
of simplex families did we identify two SLC26A4 muta-
tions; in 42% and 71% of multiplex and simplex families,
respectively, no mutations were identiﬁed. These differ-
ences between groups suggest the involvement of envi-
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Figure 4. The transcriptional activation ability of FOXI1 vari-
ants, as measured using a luciferase assay. Together with 750 ng
of empty vector (EV), FOXI1 wild-type construct (WT), or one of
the ﬁve FOXI1 mutant constructs, 250 ng of promoter-reporter
construct was transfected into COS-7 cells. Reporter-gene activity
was quantitated as “fold induction” relative to the empty vector
control. Results from three independent experiments are shown
(meanSD); the activity of each mutant FOXI1 construct has been
compared with that of the wild-type construct (P values calculated
by two-tailed Student’s t test).
Figure 5. Segregation of SLC26A4 and FOXI1 mutations in family
82230. Parents carry a single mutation in either SLC26A4 or FOXI1,
the affected child carries both mutations, and her unaffected sister
carries the SLC26A4 mutation only. Both siblings inherited the
same wild-type SLC26A4 allele from their father.
ronmental factors but are also consistent with other pos-
sibilities, including (1) the presence of large deletions in
SLC26A4 that are not recognized by our screening meth-
odology; (2) mutations in the noncoding regions of
SLC26A4, such as intronic cryptic splicing or promoter
mutations; or (3) mutations in other genes that contribute
in trans to cause a PS-EVA phenotype.
Our current PCR-based mutation-screening method
does not distinguish hemizygosity from homozygosity at
the genomic DNA level, making detection of large dele-
tions challenging. To address this problem, we completed
real-time PCR or SNP genotyping in a group of patients
( ) and failed to identify any large deletions (datanp 35
not shown). To address the second hypothesis, we com-
pleted a detailed study of the promoter region of SLC26A4
and identiﬁed a cis-regulatory element critical for SLC26A4
expression. This element is a binding target for the tran-
scription factor FOXI1 and is required for FOXI1-mediated
transcriptional activation of SLC26A4. A mutation within
this cis-element, c.103TrC, completely abolishes this
activation and was present in 9 of 429 patients, consis-
tent with this mutation having a disease-causing role in
the PS-EVA phenotype (ﬁgs. 1 and 2). Although we failed
to identify a second SLC26A4 mutation in these families,
it is not uncommon to detect a single disease-causing
SLC26A4mutation presumably in combinationwith a yet-
to-be-identiﬁed mutation either in cis or in trans (table 3).
Although other studies have described large genomic
deletions 5′ to POU3F4 (MIM 300039) and GJB2 (MIM
121011) that may contain regulatory elements causally
associated with nonsyndromic deafness at the DFN3 and
DFNB1 loci, respectively,17,18 our work is the ﬁrst to iden-
tify a speciﬁc cis-regulatory element of a deafness-related
gene and to reveal its role in the pathogenesis of nonsyn-
dromic hearing loss.
The FOXI1-binding cis-element we discovered has a
unique head-to-head structure, with FBS1 and FBS2 ori-
entated in opposite directions. Both binding sites and this
speciﬁc orientation are required for FOXI1-mediated tran-
scriptional activation (ﬁg. 2). Two recent promoter-re-
porter studies have shown that Foxi1 also activates tran-
scription of two other ion transporter genes—Slc4a9 (MIM
610207; GenBank accession number NC_000084.4) en-
coding AE4, an HCO3
/Cl exchanger in the type B in-
tercalated cells of the renal collecting-duct epithelium,19
and Atp6v1b1 (MIM 192132; GenBank accession number
NC_000072.4) encoding the B1 subunit of the vacuolar
H-ATPase proton pump in the apical pole of narrow and
clear cells of the epididymis.20 Interestingly, adjacent to
the reported Foxi1-binding cis-elements of both genes,
we observed a second putative Foxi1-binding site that
matches the FOXI1 consensus binding sequence and is in
the opposite orientation (ﬁg. 7). We hypothesize that this
unique head-to-head arrangement is a conserved FOXI1-
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Figure 6. Temporal bone histology from Slc26a4/ embryos and
Slc26a4/; Foxi/ double-heterozygous embryos at the E16.5
stage. Red arrows mark selective enlargement of the endolymphatic
duct in Slc26a4/; Foxi/ double mutants, as compared with its
normal morphology in Slc26a4/ mice. The endolymphatic duct
is also normal in the Foxi1/ mice.12
Table 3. SLC26A4 Mutation Frequency in Patients with
PS-EVAa
Mutationb

















b Mutations were detected more than ﬁve times.
binding motif to enable FOXI1 dimers to interact in a
speciﬁc protein-DNA complex structure. In support of this
hypothesis, high-resolution structural studies show that
FOXP2 (MIM 605317), another forkhead box-containing
transcription factor, dimerizes though subdomain-swap-
ping interfaces within the forkhead DNA-binding domain
to bind to multiple DNA sites.21
Consistent with our third hypothesis, that mutations in
other genes may contribute in trans to a PS-EVA pheno-
type, we identiﬁed ﬁve FOXI1 mutations in six patients
that compromise the transcriptional-activation ability of
FOXI1 (table 2 and ﬁgs. 3 and 4). These data are the ﬁrst
to linkmutations in FOXI1 to PS-EVA inhumans, although
mice homozygous for the targeted deletion of Foxi1 have
a phenotype that includes cochlear dysplasia and EVA.12
Also included in the Foxi1/ mouse phenotype are male
infertility and distal renal tubular acidosis,20,22 two abnor-
malities not yet reported in humans with PS or EVA.
On the basis of our results, we propose a dosage-depen-
dent model for the pathogenesis of PS and nonsyndromic
EVA that involves not only SLC26A4 but also its transcrip-
tional control machinery. Mutations in the SLC26A4 pro-
moter in cis and the transcription factor FOXI1 in trans,
when combined with conventional SLC26A4 mutations
or possibly other yet-to-be-identiﬁed mutations, reduce
gene expression levels to below the threshold required for
normal inner ear and/or thyroid function, leading to a
disease phenotype. Notably, in none of the six patients
with FOXI1 mutations was there a family history of hear-
ing impairment, which supports the recessive or double-
heterozygous nature of these mutations.
Although mutations in many transcription factors—in-
cluding EYA1 (MIM 601653) and SIX1 (MIM 601205) in
branchio-oto-renal syndrome (BOR [MIM 113650]), EYA4
(MIM 603550) in DFNA10 (MIM 601316), POU4F3 (MIM
602460) in DFNA15 (MIM 602459), POU3F4 in DFN3
(MIM 304400), GRHL2 (MIM 608576) in DFNA28 (MIM
608641), and PAX3 (MIM 606597), MITF (MIM 156845),
SNAI2 (MIM 602150), and SOX10 (MIM 602229) in
Waardenburg syndrome types I–IV (WS1 [MIM 277580],
WS2A [MIM 193510], WS3 [MIM 148820], andWS4 [MIM
277580])—lead to nonsyndromic or syndromic hearing
impairment, to date, no speciﬁc downstream target genes
have been found among those pathogenic pathways (He-
reditary Hearing Loss Homepage). Our work is the ﬁrst to
link a transcription factor to its speciﬁc downstream gene
in the pathogenesis of deafness.
Another interesting discovery resulting from this study
is a family in which the disease phenotype shows a double-
heterozygous inheritance pattern, with the affected child
carrying single SLC26A4 and FOXI1 mutations (ﬁg. 5). Al-
though other inheritance patterns, such as FOXI1 com-
pound heterozygosity with a second yet-to-be-identiﬁed
FOXI1 mutation, cannot be completely excluded, the
pathogenicity of the double-heterozygous genotype is
supported by several facts. First, the Slc26a4/-; Foxi1/-
mouse mutant has a similar phenotype (ﬁg. 6); second,
the FOXI1 G258E mutation reduces transcription of
SLC26A4 in vitro (ﬁg. 4); third, the SLC26A4 E29Q mu-
tation has been reported previously in families segregating
PS-EVA in association with other SLC26A4 mutations7,23;
fourth, both the affected and the unaffected child have
identical SLC26A4 genotypes, which is consistent with the
presence of additional genetic mutations in the affected
child (ﬁg. 5); and, ﬁfth, neither of these mutations has
been reported in screens of 500 chromosomes.
To our knowledge, this example of digenic inheritance
is the ﬁrst to be veriﬁed as a cause of human deafness.
Other studies have proposed a possible digenic role for
two adjacent gap-junction genes, GJB2 and GJB6, in non-
syndromic deafness at the DFNB1 locus, on the basis of
reports of two large deletions that include the 5′ end of
GJB6 and segregate with hearing loss when present in
transwith a recessive mutation inGJB2.24–26 A recent study,
however, shows that these deletions prevent expression
of both GJB2 and GJB6,18 suggesting that the deafness is
caused by loss of a yet-to-be-identiﬁed upstream cis-reg-
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Figure 7. Sequence alignment in multiple species shows the
head-to-head FOXI1-binding motif in the promoter region of
SLC26A4, SLC4A9 (GenBank accession number NC_000005.8), and
ATP6V1B1 (GenBank accession number NC_000002.10) (UCSC Ge-
nome Browser). The two adjacent FOXI1-binding sites are shown
in boxes; arrows indicate orientation. The binding sites experi-
mentally conﬁrmed to be required for gene transcriptional acti-
vation are in bold. Numbers indicate the upstream position of the
nucleotides relative to the translational start site.
ulatory element of GJB2, as opposed to loss of GJB6
expression.
As amodel of double heterozygosity inwhichmutations
in a transcription factor and its downstream target gene
combine to produce to a disease phenotype, this ﬁnding
implies that PS-EVA is a complex disease. Most genetic
disorders for which causative genes have been identiﬁed
are monogenic, and little is known about how genetic
factors interact to lead to polygenic disorders. This bigenic
disease model at the transcriptional-control level presents
a novel oligogenic disease mechanism, which may guide
gene-discovery efforts targeting complex diseases after one
or a few genes have been implicated. A dosage-dependent
model based on transcriptional control also may explain
some of the phenotypic variability that is common in
complex diseases, especially those diseases in which mul-
tiple tissues and organs are affected. Finally, our ﬁnding
may provide new therapeutic targets by which to manip-
ulate gene expression and the disease phenotype.
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